Your browser doesn't support javascript.
loading
Evaluation of Foot-and-Mouth Disease (FMD) Virus Asia1 Genotype-V as an FMD Vaccine Candidate: Study on Vaccine Antigen Production Yield and Inactivation Kinetics.
Kim, Jae Young; Park, Sun Young; Park, Sang Hyun; Lee, Gyeongmin; Jin, Jong-Sook; Kim, Dohyun; Park, Jong-Hyeon; Jeong, Seong-Yun; Ko, Young-Joon.
Afiliación
  • Kim JY; Center for FMD Vaccine Research, Animal and Plant Quarantine Agency, Gimcheon-si 177, Republic of Korea.
  • Park SY; Department of Biomedical Science, Graduate School, Catholic University of Daegu, Daegu 38430, Republic of Korea.
  • Park SH; Center for FMD Vaccine Research, Animal and Plant Quarantine Agency, Gimcheon-si 177, Republic of Korea.
  • Lee G; Center for FMD Vaccine Research, Animal and Plant Quarantine Agency, Gimcheon-si 177, Republic of Korea.
  • Jin JS; Center for FMD Vaccine Research, Animal and Plant Quarantine Agency, Gimcheon-si 177, Republic of Korea.
  • Kim D; Center for FMD Vaccine Research, Animal and Plant Quarantine Agency, Gimcheon-si 177, Republic of Korea.
  • Park JH; Center for FMD Vaccine Research, Animal and Plant Quarantine Agency, Gimcheon-si 177, Republic of Korea.
  • Jeong SY; Center for FMD Vaccine Research, Animal and Plant Quarantine Agency, Gimcheon-si 177, Republic of Korea.
  • Ko YJ; Department of Biomedical Science, Graduate School, Catholic University of Daegu, Daegu 38430, Republic of Korea.
Vaccines (Basel) ; 12(2)2024 Feb 12.
Article en En | MEDLINE | ID: mdl-38400168
ABSTRACT
South Korea has experienced outbreaks of foot-and-mouth disease (FMD) of serotypes O and A, leading to nationwide vaccination with a bivalent vaccine. Since the FMD virus (FMDV) Asia1 group-V genotype occurred in North Korea in 2007, an Asia1/MOG/05 vaccine strain belonging to the Asia1 group-V genotype was developed using a genetic recombination method (Asia1/MOG/05-R). This study aimed to evaluate the antigen productivity and viral inactivation kinetics of Asia1/MOG/05-R to assess its commercial viability. The antigen yield of Asia1/MOG/05-R produced in flasks and bioreactors was approximately 4.0 µg/mL. Binary ethylenimine (BEI) inactivation kinetics of Asia1/MOG/05-R showed that 2 mM and 1.0 mM BEI treatment at 26 °C and 37 °C, respectively, resulted in a virus titer <10-7 TCID50/mL within 24 h, meeting the inactivation kinetics criteria. During incubation at 26 °C and 37 °C, 10% antigen loss occurred, but not due to BEI treatment. When pigs were inoculated twice with the Asia1/MOG/05-R antigen, the virus neutralization titer increased to approximately 11000; therefore, it can sufficiently protect against Asia1/MOG/05-R and Asia1 Shamir viruses. The Asia1/MOG/05-R will be useful as a vaccine strain for domestic antigen banks.
Palabras clave